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Effect of dialyzer geometry during hemodialysis with cuprophane
membranes. The effect of dialyzer geometry, both flat plate (FP) and
hollow fiber (HF), on platelet and granulocyte activation during dialysis
with cuprophane membranes was studied in 12 patients. A subset of six
patients was restudied alter correction of their anemia with recombi-
nant human erythropoietin (EPO). Granulocyte count and aggregation
in vitro fell significantly (P <0.01) at 20 minutes of dialysis, followed by
a gradual return towards pre-dialysis values at 240 minutes, Malondi-
aldehyde (MDA), a product of free radical reactions generated by
activated granulocytes, increased significantly during dialysis [pre-
dialysis MDA (median, range): 8.4 (5.8 to 11.6) nmol/ml, 240 minutes
MDA: 9.7 (6.6 to 12.5) nmol/mI, P <0.01 Wilcoxon test). This increase,
however, was not affected by dialyzer geometry or EPO therapy.
Neither type of dialyzer was associated with significant platelet loss at
the end of dialysis. Whole blood platelet aggregation in vitro (sponta-
neous and collagen-induced) decreased significantly, (P < 0.01) during
dialysis, the fall in spontaneous aggregation being significantly less
following EPO therapy [spontaneous aggregation 240 minutes; pre-
EPO: 34 (13 to 52) %; post-EPO 50: (16 to 76) %, P < 0.01)1. The ratio
of the platelet release proteins /3-thromboglobulin and platelet factor 4
increased significantly during dialysis, indicating platelet activation in
vivo, although there was no effect of dialyzer geometry or EPO. Factor
VIII von Willebrand Factor antigen, a putative marker of endothelial
damage, was raised pre-dialysis, and increased further during dialysis,
irrespective of dialyzer geometry or EPO. In conclusion, dialyzer
geometry had no significant effect on granulocyte and platelet counts
and activity during hemodialysis with cuprophane membranes. Eryth-
ropoietin was associated with higher spontaneous platelet aggregation
during dialysis, which could be relevant to the development of extra-
corporeal thrombosis.
Hollow fiber (HF) or fiat plate (FP) dialyzers are currently
utilized for almost all hemodialysis treatments. Although there
have been few prospective controlled studies of these different
dialyzer designs, it seems that neither type of dialyzer offers
definite advantages over the other, such as: (a) similar cost; (b)
all biomaterials currently used in membrane manufacture can
be incorporated into both forms of dialyzers; (c) dialyzers of
equivalent performance as measured by solute clearance and
ultrafiltration coefficient are available in each form of dialyzer;
and (d) equal residual volumes. Hollow fiber dialyzers. how-
ever, have lower blood priming volumes, and have been shown
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by some [1], but not others [2], to induce less thrombocytopenia
during dialysis.
Red cells, white cells and platelets have profound effects on
microcirculatory flow, and their behavior following passage
through a dialyzer may be important. Hemodialysis is associ-
ated with the activation of white blood cells, in particular
granulocytes [3], and platelets [4]. Activated granulocytes pro-
duce reactive oxygen species (free radicals) which are pro-
thrombotic. They may also effect ischemic damage by their
physical ability to occlude the microcirculation due to endothe-
hal adherence, and the formation of aggregates [5]. Platelets
have a central role in thrombus formation, and there is some
evidence for greater platelet activation during dialysis with flat
plate designs [1]. The increase in red cell number due to the use
of recombinant human erythropoietin (EPO) is associated with
enhanced platelet aggregability [6, 7], which could further
augment any dialysis-associated coagulation changes.
In this randomized crossover study, we investigated the
effect of dialyzer geometry (FP vs. HF) on granulocyte and
platelet aggregation in vitro in a group of 12 stable hemodialysis
patients. Six of these patients, who were anemic, were restud-
ied after correction of their anemia with EPO. In this smaller
subset of patients, indirect tests of free radical activity [plasma
malondialdehyde (MDA) and thiol], the platelet release proteins
[/3-thromboglobulin (BTG) and platelet factor 4 (PF4)], and
Factor VIII von Willebrand factor antigen (FVIIIvWFAg), a
marker of endothelial damage [8], were also measured.
Methods
Patients
Twelve patients, median age 57.5 (range 20 to 75) years,
seven males, five females, were studied. Their underlying
causes of renal failure were: polycystic kidneys (3), chronic
glomerulonephritis (3), obstructive uropathy (2), unknown (2),
renovascular disease (1), and hypertensive nephropathy (1). All
had been receiving hemodialysis for at least 12 months, and had
reliable vascular access via a Cimino fistula. No patient was
receiving medication known to influence blood coagulation, and
none had chronic infection or inflammation.
They were randomly assigned to be dialyzed with either a flat
plate [Gambro Lundia (surface area) 4 N(l.0 m2), 5 N(1.1 m2) or
6 N(l.6 m2)] or hollow fiber [Gambro Alwall GFE11(1.1 m2) or
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GFE18(1.8 m2), Gambro AB, Lund, Sweden] cuprophane dia-
lyzer for a period of four weeks, following which the alternative
dialyzer of approximately comparable surface area was used for
a further four week period. All dialyzers were ethylene oxide
sterilized, and were used on a single occasion only. There were
slight differences in the non-cuprophane materials in the two
dialyzer types: FP, pressure plates (styreneacrylonitrile), side
plates (acrylonitrilebutadienestyrene), connecting plates (poly-
propylene); and HF, potting material (polyurethane) housing
and caps (polycarbonate). Duration of dialysis, blood and
dialysate flow rates, dialysis fluid [8 patients bicarbonate (ace-
tate concentration 3 mEq/liter), 4 patients acetate], target
weight, ultrafiltration and heparin dose were kept constant for
each patient throughout the study.
Blood was taken at the following time points during a dialysis
at the end of the four week period on a particular dialyzer type:
(a) arterial line, pre-dialyzer, at commencement of
dialysis
(b) venous line post-dialyzer, at commencement of
dialysis
(c) after 20 minutes of dialysis (venous line)
(d) after 240 minutes of dialysis (venous line)
The following tests were performed in all 12 patients on both
types of dialyzer, and repeated in six patients (on both dialyz-
ers) following EPO therapy.
Granulocyte aggregation in whole blood
This was measured using the method of Fisher et a! [9], on 5
ml blood anticoagulated with sodium heparin (10 lU/mi). The
sample was stirred (150 rpm) at 37°C for three minutes, follow-
ing which the synthetic aggregating agent N-formyl-methionyl-
leucyl-phenyl-alanine (fMLP, Sigma, UK) was added, and the
sample stirred for a further 1.5 minutes. Aliquots were removed
from the sample pre- and post-aggregation, and fixed in 0.2%
formalin in isotonic diluent (Isoton II, Coulter Electronics,
UK). An erythrocyte lysing agent (Zapoglobin, Coulter Elec-
tronics) was added to remove the red cells, following which the
formalin-fixed white cells were processed through a Coulter
counter (Coulter ZN, Coulter Electronics) equipped with a
particle volume analyzer (Pulse, Width and Height Analyser,
Bio-engineering Unit, University of Strathclyde). This appara-
tus transferred particle volume and frequency information to a
microcomputer where it was displayed as a curve with several
peaks representing lymphocytes, single granulocytes, and gran-
ulocyte aggregates. Granulocyte aggregation was calculated
from the percentage fall in the area under the single granulocyte
curve post-aggregation.
Platelet aggregation in whole blood
This was measured on 5 ml blood anticoagulated with 3.8%
trisodium citrate in the proportion 9:1. The sample was sepa-
rated into 1 ml aliquots which were tested for spontaneous,
collagen-induced and ADP-induced aggregation as follows:
(a) Spontaneous: Rotation (30 rpm) for six minutes at
37°C
(b) Collagen: Addition of 10 pi of a 0.6 jsg!ml collagen
solution (Semmelweis, Italy) followed by four min-
utes of incubation in a shaking water bath at 37°C
(c) ADP: Addition of 10 1.d of a 1 tM ADP solution
(Sigma, UK) followed by one minute of incubation
in a shaking water bath at 37°C,
Platelet aggregation was determined from the percentage fall
in platelet count following each aggregation procedure.
The following tests were only performed in the six patients
who were additionally treated with EPO.
Malondialdehyde (MDA)
MDA is an oxidative product of free radical reactions and
would therefore be expected to increase following granulocyte
activation and the release of toxic oxygen species. Plasma
malondialdehyde was measured using Aust's spectrophotomet-
nc assay [10] on 2.5 ml blood anticoagulated with lithium
heparin (10 lU/mi). The plasma was mixed with thiobarbituric
acid reagent (Sigma), and heated in a water bath at 100°C for 30
minutes. The optical density of the supernatant was measured
at 532 nm, and was converted to MDA concentration using an
extinction coefficient of 1.50 x l0 mol' cm (normal range:
5.0 to 8.0 nmol/ml).
Plasma thiol
Plasma thiol, mainly albumin thiol, can donate electrons to
neutralize free radicals, and is a useful measure of the degree of
oxidation of the plasma [11]. This was measured using Eliman's
method [12] on 2.5 ml blood anticoagulated with lithium heparin
(10 lU/mi). Ellman's reagent (Sigma) and 0.1 M di-sodium
hydrogen orthophosphate buffer (pH 7.6) were added to the
sample, and the mixture left at room temperature for five
minutes. Optical density was measured at 440 nm to give an
estimate of the thiol concentration of the sample (normal range:
400 to 600 mol/liter).
/3-thromboglobulin (BTG) and platelet factor 4 (PF4)
BTG and PF4 are two platelet-specific proteins released from
platelets when they aggregate, and their measure can be used as
markers of platelet activation. Both proteins are measured, and
an increase in the ratio of BTG to PF4 is indicative of platelet
activation in vivo [13]. BTG and PF4 were determined using
commercial enzyme immunoassay kits (Elisa BTG, Boehringer
Mannheim GmbH Diagnostica (Enzygnost Platelet Factor 4;
Behring, Germany). Blood (4.5 ml) was collected into tubes
containing citrate, adenosine, theophylline and dipyridamole,
cooled on ice for 15 minutes, and then centrifuged at 2000 g for
30 minutes at 4°C. The middle layer of supernatant was re-
moved for testing. Test plasma was incubated in tubes coated
with antibodies to BTG or PF4. The bound BTG/PF4 was then
allowed to couple with anti-BTG/PF4 bound to peroxidase. This
subsequently reacted with hydrogen peroxide and the chro-
mogen ortho-phenylenediamine to produce a color change
detected spectrophotometrically at 492 nm which was propor-
tional to the BTG/PF4 concentration of the sample. [Normal
ranges: BTG 10 to 40 lU/mi; PF4 2.5 (1.4 to 6.1) pg/liter].
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Factor VIII von Willebrand factor antigen (FVIIIvWFAg)
An intact functioning endothelium is required for normal
blood flow. FVIIIvWFAg was released from damaged endothe-
hum and was measured to investigate the effects on the endo-
thelium of blood that had passed through a dialyzer. A com-
mercial enzyme immunoassay was used (Dako Ltd, Denmark).
Citrated plasma was added to a microwell coated with anti-
FVIIIvWFAg. This was then further incubated with a peroxi-
dase conjugated anti-FVIIIvWFAg antibody, and reacted with
ortho-phenylenediamine to produce a color change at 492 nm,
proportional to the amount of FVIIIvWFAg in the sample. The
results were expressed as a percentage of values obtained from
pooled normal plasma.
Statistical analysis
Non-parametric statistical methods were used, and results
expressed as medians and ranges. Wilcoxon rank sum tests for
matched-paired data were used to compare pre-dialysis values
with different time points during dialysis for a single dialyzer
type, and to compare the two dialyzer types at the same time
point during dialysis. In the six patients additionally tested after
treatment with EPO, analysis of variance (Kruskal Wallis Test),
was used to determine the significance of dialyzer geometry and
EPO therapy. Changes in parameters during the course of a
dialysis were correlated with the change in plasma albumin
using Spearman's rank correlation in order to determine the
effect of hemoconcentration.
Results
There was no significant difference in the patients' pre-
dialysis plasma potassium, urea, phosphate, creatinine and
albumin on the two different dialyzer types with or without EPO
therapy. Hematocrit, however, increased significantly in the six
patients who were treated with EPO regardless of dialyzer type
[pre-EPO: 22.0 (17.5 to 30.8) %, post-EPO: 31.4 (27.2 to 40.6)
%, P < 0.01).
In all patients, granulocyte counts fell significantly to approx-
imately 25% of pre-dialysis values 20 minutes into dialysis. This
was followed by a return to just above pre-dialysis values (P <
0.05, HF) at 240 minutes (Fig. 1). With both types of dialyzer,
granulocyte aggregation fell in parallel with the fall in granulo-
cyte count to approximately 25% of pre-dialysis levels at 20
minutes. There was, however, no significant difference between
the two dialyzer types at any other time point during dialysis
(Fig. 1). EPO treatment had no significant effect on granulocyte
count or aggregation during dialysis.
In patients dialyzed with FP dialyzers there was a slight, but
significant (P < 0.05), fall in platelet count 20 minutes into
dialysis [FP pre-dialysis: 151 (78 to 253) x 109/hiter; 20 mm: 135
(71—244) x l09/liter}. By the end of dialysis (240 mm) platelet
counts had returned to levels which were not significantly
different from those pre-dialysis. A fall in platelet count at 20
minutes was not observed when patients were dialyzed with HF
dialyzers, however, with this dialyzer type, platelet counts
tended to overshoot at the end of dialysis (P < 0.05 vs.
pre-dialysis) to levels significantly higher (P <0.02) than those
observed with FP dialyzers. [HF pre-dialysis: 170(106 to 262) x
109/liter; HF 240 mm: 195 (155 to 290) x 109/liter; FP pre-
dialysis: 151 (78 to 253) x 109/liter; FP 240 mm: 153 (100 to 249)
x 109/liter]. There was no significant difference between the
two dialyzer types at any other time points during dialysis (Fig.
2), and in six patients there was no additional effect of EPO on
platelet count. Spontaneous and collagen-induced platelet ag-
gregation fell significantly during the course of dialysis irrespec-
tive of dialyzer geometry (Fig. 2), but there was no significant
change in aggregation induced by ADP. In the six patients
treated with EPO, spontaneous platelet aggregation was signif-
icantly higher (P < 0.01) at 20 and 240 minutes of dialysis
compared to pre-EPO [20 mm; pre-EPO: 37 (19 to 82)%;
post-EPO: 58 (40 to 91)%, 240 mm; pre-EPO: 34 (13 to 52)%,
post-EPO: 50 (16 to 76)%J. These findings were not influenced
by dialyzer geometry.
In the six patients studied before and after EPO treatment,
MDA levels were higher pre-dialysis than in normal non-uremic
subjects, and increased further during the course of dialysis
(Table 1), whereas plasma thiol was lower than normal pre-
dialysis, but increased during dialysis. This increase, however,
was significantly correlated with the change in plasma albumin
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Fig. 1. Change in granulocyte count and
aggregation during dialysis with flat plate (•)
and hollow fiber (A) cuprophane membranes
in 12 hemodialysis patients. (Horizontal lines
depict median values.)
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Table 1. Change in malondialdehyde, thiol, /3-thromboglobulin, platelet factor 4 and factor VIII von Willebrand factor antigen during
hemodialysis in six patients
Pre-HD
Post- 1st
HD Post-20 mm
Post-240
mm
Malondialdehyde nmol/ml 8.40
(5.8—11.6)
8.55
(2.3—11.5)
9. 15a
(7.1—12.3)
97Ø
(6.6—12.5)
Thiol u.mol/liter 314.0
(188—444)
335.5
(74—477)
353•5a
(294-531)
4535
(351—747)j3-thromboglobulin lU/mi 145.5
(85.6—172.8)
156.5
(71.7—179.0)
160.9a
(92.8—198.6)
168.8a
(98.6—203.6)
Platelet factor 4 p.g/liter 37.1
(9.2—140.0)
37.1
(19.2—237.5)
37.2
(14.3—241.6)
21.4
(3.4-223.5)
Factor VIII von Willebrand factor antigen 199.5 211.5 219.Oa 262.5a
% normal pooi (94—390) (75—411) (100—400) (102—545)
Values are expressed as medians and ranges. Normal ranges are: malondialdehyde (N = 23), 6.3 (5.4—8.7) nmol/ml; thiol (N = 23), 445 (358—501)
smo1/l; /3-thromboglobulin, 10—40 lU/mI; platelet factor 4, 1.4-6.1 pg/liter.
a P < 0.01, Wilcoxon versus pre-dialysis
due to hemoconcentration (r = 0.671, P < 0.01). The platelet
release proteins, BTG and PF4, were elevated by comparison
with normals pre-dialysis. BTG significantly increased during
the course of dialysis, whereas PF4 decreased, but not signifi-
cantly (Table 1). The ratio of BTG to PF4 increased during
dialysis from 3.7 (1.1 to 17.1) pre-dialysis to 7.3 (0.8 to 44.1) at
240 minutes (P < 0.01). FVIIIvWFAg was also increased
pre-dialysis and rose significantly during dialysis (Table 1).
Changes in all these parameters were not influenced by dialyzer
geometry or EPO therapy, and only plasma thiol correlated
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significantly with the change in albumin due to hemoconcentra-
tion.
Discussion
This study has demonstrated further evidence for the activa-
tion of granulocytes and platelets during the course of dialysis
with cuprophane membranes. These findings, however, were
not greatly influenced by dialyzer geometry or erythropoietin
treatment.
In keeping with the findings of Daugirdas et al [14], we
demonstrated a comparable fall in granulocyte count during
dialysis with FP and HF dialyzers. In addition, concomitant
with the fall in granulocyte count, we also observed a fall in
granulocyte aggregation in vitro. We believe this to represent
removal of a more active subpopulation of granulocytes from
the circulation due to activation and aggregation in vivo with
subsequent deposition in the pulmonary vasculature, The re-
maining cells were therefore more resistant to aggregation in
vitro.
Malondialdehyde levels were increased pre-dialysis and in-
creased further during the course of dialysis. These observa-
tions have also been demonstrated by Miguel et al [15], and
provide indirect evidence for enhanced free radical activity in
hemodialysis patients, with further generation of reactive oxy-
gen species during the course of dialysis due to granulocyte
activation. We also found reduced plasma thiol levels pre-
dialysis, indicating lowered plasma antioxidant capacity. Al-
though plasma thiol might have been expected to decrease
during dialysis, due to the generation of free radicals from
granulocytes, we in fact observed an increase. This correlated
with the change in albumin concentration and was therefore
most likely due to the effects of hemoconcentration. Changes in
plasma MDA and thiol were not affected by dialyzer geometry
or EPO therapy.
Neither type of dialyzer was associated with a significant loss
of platelets at the end of dialysis. Platelet aggregation (sponta-
neous and collagen-induced) decreased during the course of
dialysis, reflecting the development of a population of "ex-
hausted" platelets which had undergone the release reaction
upon initial exposure to cuprophane, during the earlier stages of
dialysis. In keeping with this, there was an increase in the ratio
of BTG to PF4 during dialysis confirming platelet activation in
vivo. Levels of BTG and PF4 were also significantly elevated in
the pre-dialysis samples. Although clearance of BTG is im-
paired in renal failure [16], the elevated pre-dialysis PF4 would
suggest a degree of non-dialysis-related platelet activation in
these patients. Changes in platelet aggregation were not af-
fected by dialyzer geometry, but were affected by EPO, such
that higher spontaneous aggregation was observed by 20 min-
utes and at the end of dialysis in EPO treated patients compared
to pretreatment. The increased red cell count produced by EPO
has previously been shown by our group to enhance spontane-
ous platelet aggregation, possibly by a combination of physical
and chemical effects [6], and may contribute to the increased
tendency to extracorporeal thrombosis observed with this ther-
apy [17].
The significance of the increase in FVIIIvWFAg during
dialysis is unclear. Measurement of FVIIIvWFAg has been
shown to be a marker of endothelial damage in other patients
with chronic vascular disease [8]. In hemodialysis patients it is:
increased pre-dialysis; too large to be removed by dialysis; and
its structure is not changed during dialysis [181. In our study,
the change in FVIIIvWFAg could not be explained by hemo-
concentration effects alone. It is possible that free radicals
generated during hemodialysis are harmful to the patients'
vaseulature, and that this damage is reflected by the rise in
FVIIIvWFAg. Certainly, in patients who receive renal trans-
plants, cessation of dialysis is associated with a reversal of
uremic vasculopathy [19].
In conclusion, dialyzer geometry (flat plate and hollow fiber)
does not influence granulocyte or platelet number and activa-
tion during dialysis with cuprophane membranes. Patients
treated with EPO may be more prone to extracorporeal throm-
bosis due to the effect of the increased red cell number on
platelet function.
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